{
    "clinical_study": {
        "@rank": "62302", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating\n      children who have relapsed or refractory neuroblastoma."
        }, 
        "brief_title": "Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma", 
        "completion_date": {
            "#text": "September 2006", 
            "@type": "Actual"
        }, 
        "condition": "Neuroblastoma", 
        "condition_browse": {
            "mesh_term": "Neuroblastoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate to rebeccamycin analogue in children with relapsed or\n           refractory neuroblastoma.\n\n        -  Determine the toxicity of this drug in these patients.\n\n        -  Identify and establish in vitro biologic correlates of clinical responses and toxicity\n           of this drug in these patients.\n\n      OUTLINE: Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5. Treatment\n      repeats every 3 weeks for at least 2 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      PROJECTED ACCRUAL: This study will accrue up to 30 patients within 1.5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven relapsed or refractory neuroblastoma\n\n          -  Measurable disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Children\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 2 months\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin less than 1.5 mg/dL\n\n          -  SGOT and SGPT less than 2.5 times upper limit of normal (ULN)\n\n          -  Adequate liver function unless due to disease\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  Adequate renal function unless due to disease\n\n        Other:\n\n          -  No other serious concurrent illness\n\n          -  No active uncontrolled infection\n\n          -  Not pregnant\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Recovered from prior immunotherapy\n\n          -  Prior autologous bone marrow transplantation allowed\n\n          -  No concurrent immunotherapy\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy and recovered\n\n          -  No other concurrent systemic chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Recovered from prior radiotherapy\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003737", 
            "org_study_id": "98-095", 
            "secondary_id": [
                "CDR0000066852", 
                "NCI-T98-0041"
            ]
        }, 
        "intervention": {
            "intervention_name": "becatecarin", 
            "intervention_type": "Drug"
        }, 
        "keyword": "recurrent neuroblastoma", 
        "lastchanged_date": "June 24, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-98095"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Tanya Trippett, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Response (complete response, very good partial response, or partial response)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Freedom from progression", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003737"
        }, 
        "secondary_outcome": {
            "measure": "Toxicity", 
            "safety_issue": "Yes"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}